Common adverse event reporting form
Executive Summary
Final version of a common form for reporting adverse events associated with drugs, biologics and devices will be the topic of a June 3 FDA-sponsored conference involving representatives from the affected industries and health care professionals. A final version of the form is slated for Federal Register publication around the time of the meeting; a draft was issued in February. Health Research Group has asked FDA to delay implementation of the new form until after its effectiveness is compared to existing forms in a six-month field trial.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth